These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 9570425

  • 1. Potential cardioprotective effect of mibefradil in the long-term treatment of hypertension.
    Waeber B.
    Cardiology; 1998; 89 Suppl 1():16-22. PubMed ID: 9570425
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
    Brogden RN, Markham A.
    Drugs; 1997 Nov; 54(5):774-93. PubMed ID: 9360062
    [Abstract] [Full Text] [Related]

  • 4. Differential properties of mibefradil in hypertension and angina.
    Kobrin I.
    J Hypertens Suppl; 1997 Dec; 15(5):S33-40. PubMed ID: 9481614
    [Abstract] [Full Text] [Related]

  • 5. The relevance of T-type calcium antagonists: a profile of mibefradil.
    Glasser SP.
    J Clin Pharmacol; 1998 Aug; 38(8):659-69. PubMed ID: 9725540
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
    Noll G, Lüscher TF.
    Cardiology; 1998 Aug; 89 Suppl 1():10-5. PubMed ID: 9570424
    [Abstract] [Full Text] [Related]

  • 9. Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension.
    Oparil S, Bernink P, Bursztyn M, Carney S, Kobrin I.
    Am J Cardiol; 1997 Aug 21; 80(4B):12C-19C. PubMed ID: 9286849
    [Abstract] [Full Text] [Related]

  • 10. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
    Oparil S, Kobrin I, Abernethy DR, Levine BS, Reif MC, Shepherd AM.
    Am J Hypertens; 1997 Jul 21; 10(7 Pt 1):735-42. PubMed ID: 9234827
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension.
    Lacourcière Y, Poirier L, Lefebvre J, Archambault F, Dalle Ave S, Ward C, Lindberg E.
    Am J Hypertens; 1997 Feb 21; 10(2):189-96. PubMed ID: 9037327
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Use of calcium channel blockers in hypertension.
    Conlin PR, Williams GH.
    Adv Intern Med; 1998 Feb 21; 43():533-62. PubMed ID: 9506192
    [Abstract] [Full Text] [Related]

  • 17. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients.
    Höglund C, Cifkova R, Mimran A, Tenczer J, Watt A, Wilkins MR, Lindberg E.
    Cardiology; 1998 May 21; 89(4):263-70. PubMed ID: 9643273
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure.
    Mulder P, Richard V, Compagnon P, Henry JP, Lallemand F, Clozel JP, Koen R, Macé B, Thuillez C.
    J Am Coll Cardiol; 1997 Feb 21; 29(2):416-21. PubMed ID: 9014998
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.